



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BTSA1

Cat. No.:	HY-123054
CAS No.:	314761-14-3
Molecular Formula:	C ₂₁ H ₁₄ N ₆ OS ₂
Molecular Weight:	430.51
Target:	Bcl-2 Family; Apoptosis
Pathway:	Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (58.07 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.3228 mL	11.6141 mL	23.2283 mL
	5 mM		0.4646 mL	2.3228 mL	4.6457 mL
	10 mM		0.2323 mL	1.1614 mL	2.3228 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

BTSA1 is a potent, high affinity and orally active BAX activator with an IC₅₀ of 250 nM and an EC₅₀ of 144 nM. BTSA1 binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis^[1].

IC₅₀ & Target

Bax 250 nM (IC ₅₀)	Bax 144 nM (EC ₅₀)
-----------------------------------	-----------------------------------

In Vitro

BTSA1 (5 μM; 6-24 hours; human AML cell lines) treatment reduced viability of all AML cell lines and displays substantial cell death? activity within 6 hours^[1].

?BTSA1 (2.5-10 μM; 6 hours; NB4 cells) treatment induces BAX translocation coincided with the release of cytochrome c from the mitochondria to the cytosol. Significant BAX mitochondrial translocation is induced in a BTSA1 dose-dependent manner^[1].

?BTSA1 (0.15625-10 μM; 4-24 hours; OCI-AML3 cells) treatment induces dose-dependent caspase-3/7 activation in OCI-AML3 cells. Caspase-3/7 activation is monitored within 4-24 hours and maximal caspase-3/7 activation is detected in 4 hours^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assays^{sup>[1]}

Cell Line:	Human AML cell lines<
Concentration:	5 μ M
Incubation Time:	6 hours, 12 hours, 24 hours
Result:	Reduced viability of all AML cell lines. Displayed substantial cell death activity within 6 hours.

Western Blot Analysis^[1]

Cell Line:	NB4 cells
Concentration:	2.5 μ M, 5 μ M, 10 μ M
Incubation Time:	6 hours
Result:	Significant BAX mitochondrial translocation was induced in a dose-dependent manner.

Apoptosis Analysis^[1]

Cell Line:	OCI-AML3 cells
Concentration:	0.15625 μ M, 0.3125 μ M, 0.625 μ M, 1.25 μ M, 2.5 μ M, 5 μ M, 10 μ M
Incubation Time:	4 hours, 6 hours, 8 hours, 12 hours, 24 hours
Result:	Induced dose-dependent caspase-3/7 activation in OCI-AML3 cells. Caspase-3/7 activation was monitored within 4-24 hr and maximal caspase-3/7 activation was detected in 4 hr.

In Vivo

BTSA1 (10 mg/kg; intraperitoneal injection; every two days; NOD-SCID IL2R γ null (NSG) mice) treatment significantly increases survival when compared to vehicle-treated mice. BTSA1 treatment induces significant suppression of leukemia growth^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD-SCID IL2R γ null (NSG) mice (6-8 weeks old) with THP-1 cells ^[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; every two days
Result:	Significantly increased survival when compared to vehicle-treated mice.

CUSTOMER VALIDATION

- Int J Mol Sci. 2023 May 11, 24(10), 8609.

See more customer validations on www.MedChemExpress.com

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA